819 reports of this reaction
3.5% of all DURVALUMAB reports
#3 most reported adverse reaction
PNEUMONITIS is the #3 most commonly reported adverse reaction for DURVALUMAB, manufactured by AstraZeneca Pharmaceuticals LP. There are 819 FDA adverse event reports linking DURVALUMAB to PNEUMONITIS. This represents approximately 3.5% of all 23,251 adverse event reports for this drug.
Patients taking DURVALUMAB who experience pneumonitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PNEUMONITIS is moderately reported among DURVALUMAB users, representing a notable but not dominant share of adverse events.
In addition to pneumonitis, the following adverse reactions have been reported for DURVALUMAB:
The following drugs have also been linked to pneumonitis in FDA adverse event reports:
PNEUMONITIS has been reported as an adverse event in 819 FDA reports for DURVALUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PNEUMONITIS accounts for approximately 3.5% of all adverse event reports for DURVALUMAB, making it one of the most commonly reported side effect.
If you experience pneumonitis while taking DURVALUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.